Annovis Bio, Inc. - 8-K Filing
Annovis Bio announced on May 20, 2026, that it entered into an underwriting agreement with Canaccord Genuity LLC for a public offering to sell 7,895,000 shares of common stock and accompanying warrants to purchase up to 7,105,500 additional shares. The combined price per share is $1.90, generating expected gross proceeds of approximately $15 million before expenses. Funds will be used for clinical development of Buntanetap in Alzheimer’s and Parkinson’s disease studies. (Items: 1.01 Entry into a Material Definitive Agreement, 7.01 Regulation FD Disclosure On May 19, 2026, the Company issued a press release announcing the launch of the Offering, 9.01 Financial Statements and Exhibits Exhibit Number Description 4)
Tickers: $ANVS